Table 9.

Comparison in terms of average balanced accuracy with existing studies in 100 feature selection runs (mean ± std).

Dataset	Method									Proposed BEV
	FSBACOM	TFSACO	IRRFSACO	TSHFS-ACO	PSO	ECLPSO	CSO	VLPSO	ERM-FS
Lung cancer	82.81 ± 1.54	88.84 ± 2.24	86.67 ± 3.13	88.62 ± 0.84	78.77 ± 1.53	77.91 ± 1.98	87.72 ± 2.93	87.60 ± 1.20	93.25 $\pm$ 0.01	100.0 $\pm$ 0.00
11 tumor	80.21 ± 1.76	81.71 ± 1.17	78.85 ± 1.60	85.12 ± 1.30	71.81 ± 1.75	71.09 ± 1.20	79.52 ± 2.35	82.38 ± 1.94	80.26 $\pm$ 0.02	87.00 $\pm$ 3.49
Leukemia 2	92.22 ± 2.12	92.44 ± 2.04	87.72 ± 2.44	95.00 ± 1.43	89.83 ± 1.00	89.82 ± 1.20	91.71 ± 3.16	91.56 ± 2.05	98.12 $\pm$ 0.01	100.0 $\pm$ 0.00
Prostate	83.98 ± 1.90	88.73 ± 2.02	91.05 ± 2.31	91.57 ± 1.21	86.00 ± 1.49	85.46 ± 1.41	88.99 ± 2.68	88.48 ± 1.93	96.12 $\pm$ 0.01	100.0 $\pm$ 0.00
Brain tumor 2	67.21 ± 4.48	72.33 ± 3.29	72.58 ± 4.58	76.08 ± 3.68	61.99 ± 2.91	63.20 ± 2.60	80.44 ± 6.28	70.29 ± 5.25	89.23 $\pm$ 0.03	98.00 $\pm$ 5.37
Brain tumor 1	74.83 ± 1.78	74.04 ± 3.33	63.88 ± 4.53	71.42 ± 3.97	73.73 ± 2.21	73.87 ± 2.37	79.93 ± 3.09	70.58 ± 2.78	83.26 $\pm$ 0.04	89.00 $\pm$ 0.00
9 tumor	40.83 ± 5.49	45.83 ± 5.33	40.00 ± 3.80	50.67 ± 5.53	42.72 ± 1.42	41.33 ± 1.48	59.50 ± 3.72	47.33 ± 4.23	64.44 $\pm$ 0.07	64.80 $\pm$ 7.04
DLBCL	89.48 ± 2.00	91.22 ± 6.43	91.53 ± 3.66	93.95 ± 1.68	83.67 ± 1.52	82.44 ± 2.01	94.30 ± 4.05	91.03 ± 3.85	98.09 $\pm$ 0.02	100.0 $\pm$ 0.00
Leukemia 1	84.68 ± 4.23	93.90 ± 1.13	80.32 ± 2.78	94.81 ± 2.35	80.60 ± 2.55	80.88 ± 2.28	88.45 ± 3.90	96.05 ± 2.62	97.93 $\pm$ 0.01	100.0 $\pm$ 0.00
SRBCT	88.96 ± 3.00	98.71 ± 0.89	89.13 ± 2.35	99.42 ± 0.53	89.51 ± 1.56	88.10 ± 1.57	93.29 ± 5.52	98.88 ± 0.70	100 $\pm$ 0.00	100.0 $\pm$ 0.00

Significant values are in bold.